Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Amgen Astellas Biopharma K.K. and Astellas Pharma Inc Announces Submission of Application for Investigational Osteoporosis Medication Romosozumab in Japan

12/20/2016 | 08:00am EDT

Amgen Astellas BioPharma K.K. and Astellas Pharma Inc. announced that Amgen Astellas submitted an application seeking marketing approval of romosozumab (AMG785) for the treatment of osteoporosis for those at high risk of fracture for review to the Ministry of Health, Labour and Welfare in Japan. Amgen Astellas and Astellas are co-developing romosozumab in Japan. Romosozumab is an investigational monoclonal antibody that works by binding and inhibiting the activity of sclerostin, a glycoprotein secreted by osteocytes in bone, thereby increasing bone formation and decreasing bone resorption.


© S&P Capital IQ 2016
All news about ASTELLAS PHARMA INC.
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Prog..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approac..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in E..
MT
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) fo..
PU
More news
Financials
Sales 2022 1 325 B 12 044 M 12 044 M
Net income 2022 196 B 1 779 M 1 779 M
Net cash 2022 478 B 4 341 M 4 341 M
P/E ratio 2022 17,7x
Yield 2022 2,65%
Capitalization 3 500 B 31 855 M 31 819 M
EV / Sales 2022 2,28x
EV / Sales 2023 1,92x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 889,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura Representative Director, VP & Head-Finance
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.18.51%31 855
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456